BioSpace News Archive

GE HealthCare announced the next-generation bkActiv is now available for guiding urology, colorectal and pelvic floor surgical procedures.

Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT 1A agonist activity, for the treatment of generalized anxiety disorder (GAD).

Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members of its team, joining as Senior Vice President of Antibody Discovery Services and Senior Vice President of Therapeutic Discovery Strategies, respectively.

Xencor, Inc. today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.

Hoth Therapeutics, Inc. today announced it has signed a Letter of Intent to merge with Algorithm Sciences, Inc. (“Algorithm”) a company focused on Pulmonary Arterial Hypertension (PAH).

Pressure BioSciences, Inc. today provided a progress update on their exciting April 21, 2023, announcement.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has kicked off its 2023 Curiosity Cube tour in North America and Europe.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted new clinical data supporting the T2Bacteria® Panel and the T2Candida® Panel, that was recently presented at the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Copenhagen, Denmark.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, May 3, 2023, to review the company’s first quarter 2023 financial results and provide business updates.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023.